Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Which peptides are studied in relation to hyperpigmentation?

A research-supply review of the compounds investigated in hyperpigmentation models, including setmelanotide, bakuchiol, kojic acid, and Curcuma xanthorriza Roxb., with notes on which findings are clinical, which are in v

peptides-pro Editorial

The question of which peptides are studied in relation to hyperpigmentation has no single answer, because the literature does not converge on one molecule. The compounds most frequently examined in this context are not classical signal peptides at all: setmelanotide, a cyclic peptide analogue and melanocortin 4 receptor (MC4R) agonist, has been characterised in monogenic obesity cohorts rather than in pigmentary disorders [2], while the pigmentation literature is dominated by small-molecule and botanical actives such as bakuchiol, kojic acid, azelaic acid, retinal, and Curcuma xanthorriza Roxb. [8][11][12][5]. Where a peptide backbone does appear, it is as a receptor-directed tool — setmelanotide acting at MC4R within the leptin-melanocortin signalling pathway — and the melanocortin receptor family is the receptor class around which that work centres [2].

Identifiers are sparse in the available evidence. Setmelanotide is described by its receptor target and pharmacological class rather than by sequence, formula, or molecular weight in the sources reviewed here [2]. The pigmentation actives are likewise reported by name and mechanism: bakuchiol is described as plant-derived with inhibitory effects on melanin synthesis [8]; kojic acid is treated as a natural hypopigmenting agent with recognised delivery limitations [12]; Curcuma xanthorriza Roxb. is reported to act by inhibiting tyrosinase and reducing MITF transcription [5]. No sequence data, CAS numbers, or molecular weights are supplied for any of these compounds in the evidence block, and none are asserted here.

Research Studies

Setmelanotide and MC4R signalling in monogenic obesity

Setmelanotide is a melanocortin 4 receptor agonist studied in people with rare monogenic obesity conditions affecting the leptin-melanocortin signalling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations [2]. A case report described a 40-year-old female with a heterozygous PCSK1 N221D (c.661 A>G) variant and severe early-onset treatment-resistant obesity, who achieved a total weight loss of 11.8% on setmelanotide after previous suboptimal response to bariatric surgery and conventional obesity medications [2]. This work concerns energy balance, not pigmentary endpoints.

Setmelanotide and graft function in paediatric kidney transplant recipients

A separate evaluation followed two children with Bardet-Biedl syndrome treated with setmelanotide after kidney transplantation, collecting anthropometric, hunger, metabolic, graft-function, cyclosporine, and genetic data [1]. Patient 1, a 17-year-old boy with a homozygous pathogenic SDCCAG8 exon deletion, improved over 12 months: weight 55.6 to 48.0 kg, BMI 26.6 to 23.0 kg/m2, BMI-for-age z-score +1.60 to +0.43, maximal-hunger score 8/10 to 5/10, and HbA1c 6.5% to 5.1% [1]. Again, no pigmentation outcome was measured.

Bakuchiol and post-inflammatory hyperpigmentation

Bakuchiol is derived from plants and has inhibitory effects on melanin synthesis, which the investigators frame as a rationale for its evaluation in post-inflammatory hyperpigmentation (PIH) [8]. PIH is described as an acquired hypermelanosis occurring after cutaneous inflammation or injury, frequently affecting darker-skinned individuals [8]. The registered study aims to evaluate bakuchiol in PIH using a previously validated model, compared against acne-induced PIH [8].

Kojic acid and melanosome transfer

Kojic acid is characterised as a natural hypopigmenting agent, with the reviewed literature covering its biological activities, delivery challenges, and nanotechnology-based strategies [12]. Hyperpigmentation is described in that work as a multifaceted process involving overproduction and uneven distribution of melanin, with treatment focused mainly on melanocyte reduction and stopping melanosome production or transfer [12].

Curcuma xanthorriza Roxb. and tyrosinase inhibition in melasma

Curcuma xanthorriza Roxb., a plant native to Indonesia, is reported to operate by inhibiting the tyrosinase enzyme and reducing MITF transcription [5]. The registered trial evaluates a 10% cream in melasma, an acquired hyperpigmentation disorder with multifactorial aetiology and complex pathogenesis [5]. The background notes that hydroquinone remains the first-line depigmentation agent for melasma but is often associated with adverse effects, motivating the search for alternatives [5].

Retinal and azelaic acid in blemish-prone skin

An eight-week randomised prospective split-face, vehicle-controlled study examined a novel anhydrous 0.1% retinal and 10% azelaic acid concentrate for blemish-prone skin [11]. Blemish-prone skin is described as driven by follicular hyperkeratinisation, excessive sebum production, microbial dysbiosis, and inflammation, often accompanied by post-inflammatory erythema and hyperpigmentation [11].

Combination topical regimens and post-inflammatory hyperpigmentation in skin of colour

A single-centre, prospective, non-blinded, non-randomised 12-week study evaluated a comprehensive skincare regimen for reduction of PIH in skin-of-colour patients [4]. The regimen features a pigment balancing peel combining glycolic acid, lactic acid, kojic acid, vitamin C, and emblica, supplemented with a hydrating gel, a discoloration product, a cleansing gel, and a brightening sunscreen [4].

Oral tranexamic acid with 1064-nm Q-switched fractional laser in melasma

A clinical observation examined 1064-nm Q-switched fractional laser combined with oral tranexamic acid in melasma, described as a common acquired condition of symmetric facial hyperpigmentation with higher prevalence in females and darker skin types [7]. The 1064-nm wavelength is reported to be effectively absorbed by pigment, leading to damage of pigment and melanocytes [7].

Sun protection and post-surgical hyperpigmentation

A randomised split-wound study assessed whether sun protection influences the aesthetic outcome of post-surgical scars following reconstruction of Mohs micrographic surgery defects via linear repair [6]. Half of each wound received zinc-containing sunscreen and half did not; at three months, scars were evaluated with the patient observer scar assessment scale (POSAS) and a colorimeter measuring vascularity and hyperpigmentation against surrounding skin [6].

Glutathione-containing effervescent product and facial dark spots

A randomised, double-blinded, single-centre, two-arm, placebo-controlled prospective study evaluated the clinical safety, efficacy, and in-use tolerability of an effervescent glutathione-containing tablet product in subjects with facial hyperpigmentation and dark spots [3].

If you are reading this for personal health reasons

The materials described here are supplied for laboratory research use only, and we do not provide dosing, administration, or medical guidance of any kind. Nothing on this page is a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp